SOMERSET, NJ, February 17, 2011 – Alan Hendricker, Ph.D., Principal Scientist of Structural Chemistry, and Thomas Feinberg, Ph.D., Director of Structural Chemistry, at Catalent Pharma Solutions will have prominent roles at this year’s PQRI workshop entitled “Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products (PODP).” The workshop will be held at the Hyatt Regency in Bethesda, MD on February 22-23, 2011. Dr. Hendricker will be presenting “PODP Approach to Acquire Extractable Profile Data” that will include topics such as PODP extractables protocol, along with a summary and discussion of results and best practice recommendations for extractables testing. Coinciding with his presentation, Dr. Hendricker will also be participating in a poster session presenting data from an extractables studies entitled, “Controlled Extraction Study on Low Density Polyethylene (LDPE).” Dr. Feinberg, who is on the PQRI organizing committee this year, will be serving as the moderator and make closing remarks for the first day’s activities.
This year’s PQRI workshop examines the affects substances extracted by drug products from their container closure systems have on drug product’s effectiveness. With limited direction from regulatory authorities regarding the analysis and toxicological safety assessment of such substances, the PQRI has issued a recommendation to provide a scientific method and process to identify, quantify and qualify leachables and/or extractables in orally inhaled and nasal drug products (OINDP). Recognizing that the OINDP recommendations could have general applicability in other dosage forms such as PODP, this year’s PQRI workshop will be the first opportunity of the PODP leachables and extractables work group to present and discuss its findings. The experience and insights of the workshop participants shared at these working sessions will contribute to ongoing development of the recommendations.
Dr. Alan Hendricker is the Principal Scientist of Structural Chemistry at Catalent’s facility in Research Triangle Park, NC. He initially worked at Magellan Laboratories in its structural chemistry group specializing in mass spectral extractable/leachable profiling of container-closure systems, device componentry, drug product packaging materials and drug products for the pharmaceutical industry. Dr. Hendricker utilizes analytical techniques such as gas chromatography mass spectrometry (GC-MS), liquid chromatography mass spectrometry (LC-MS), inductively coupled plasma mass spectrometry (ICP-MS), and headspace analysis for volatile impurities. In 2006 Dr. Hendricker became a member of the PQRI working group and helped to develop the Safety Threshold and Best Practices for Extractables and Leachables in OINDP.
For more information about the workshop and to view the program in its entirety, visit http://www.pqri.org/index.asp.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,000 people at 28 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
